12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lupron Depot-PED leuprolide acetate regulatory update

FDA approved an sNDA for 11.25 and 30 mg of a 3-month formulation of Lupron Depot-PED leuprolide acetate to treat central...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >